Donate to Research

Blog

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial

JAMA Oncol. 2024 Feb 15:e236789. doi: 10.1001/jamaoncol.2023.6789

Peter W Szlosarek^1 2 3, Benjamin C Creelan⁴, Thomas Sarkodie², Luke Nolan⁵, Paul Taylor⁶, Olga Olevsky⁷, Federica Grosso⁸, Diego Cortinovis⁹, Meenali Chitnis¹⁰, Amy Roy¹¹, David Gilligan¹², Hedy Kindler¹³, Dionysis Papadatos-Pastos¹⁴, Giovanni L Ceresoli¹⁵, Aaron S Mansfield¹⁶, Anne Tsao¹⁷, Kenneth J O’Byrne¹⁸, Anna K Nowak¹⁹, Jeremy Steele³, Michael Sheaff³, Chiung-Fang Shiu²⁰, Chih-Ling Kuo²⁰, Amanda Johnston²⁰, John Bomalaski²⁰, Marjorie G Zauderer²¹, Dean A Fennell²²; ATOMIC-Meso Study Group

Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma

Creaney, J. et al. Genome Med 14, 58 (2022).

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres

Fennell, D. et al. BMJ Open 13, e073120 (2023).

Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways. Genes Chromosomes Cancer (2023).

Jama, M. et al. Genes Chromosomes Cancer (2023).

Family Matters: Germline Testing in Thoracic Cancers

BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms

Singh, A. et al.

Oncogene 42, 572-585 (2023).

Accelerating innovations in systemic therapy for pleural mesothelioma

Fennell, D. A. & Bzura, A. Nat Cancer 3, 902-904 (2022).

Immunotherapy approaches for malignant pleural mesothelioma.

Fennell, D. A., Dulloo, S. & Harber, J. Nat Rev Clin Oncol 19, 573-584 (2022).

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

Fennell, D. A. et al. EClinicalMedicine 48, 101432 (2022).

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

Zauderer, M. G. et al. Lancet Oncol 23, 758-767 (2022).